Epigenetic dysregulation in meningiomas.

Area of Science:

• Neuro-oncology
• Epigenetics
• Genomics

Background:

• Meningiomas are common primary brain tumors, often benign but sometimes aggressive.
• Current treatments lack efficacy, and DNA methylation patterns offer better predictive value than histology.
• Differences in DNA methylation between meningiomas and normal dura are largely unknown.

Purpose of the Study:

• To investigate DNA methylation differences between meningiomas and normal dura.
• To identify distinct DNA methylation patterns in meningiomas.
• To explore the role of epigenetic dysregulation in meningioma pathogenesis.

Main Methods:

• Whole-exome sequencing and methylation array profiling on 12 dura/meningioma pairs.
• SNP genotyping and methylation array profiling on 19 additional meningiomas (grades I-III).
• Multimodal data analysis to identify DNA methylation patterns.

Main Results:

• Identified 4 distinct DNA methylation patterns in meningiomas.
• Diffuse DNA hypomethylation in malignant meningiomas distinguished them from lower-grade tumors.
• Discovered hypomethylation of FOXC1 and FOXCUT promoters in all tumors and meningioma-dura pairs.
• Observed an epigenetic continuum of increasing hypermethylation with increasing tumor grade.

Conclusions:

• Epigenetic dysregulation of FOXC1 and cranial patterning genes may play a role in meningioma formation.
• Polycomb inhibitors show potential as a therapeutic strategy for malignant meningiomas.
• DNA methylation profiling provides valuable insights into meningioma heterogeneity and behavior.